Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.

Takahiro MasudaKen OharaIzumi NagayamaRyo MatsuokaTakuya MurakamiSaki NakagawaKentanro OkaMaki AsakuraYusuke IgarashiYukimura FukayaYasuharu MiyazawaAkito MaeshimaTetsu AkimotoOsamu SaitoDaisuke Nagata

Published in: International urology and nephrology (2019)

Serum albumin levels predict the body fluid response to tolvaptan in CKD patients. Tolvaptan may be a promising therapeutic option for ameliorating body fluid retention, especially in patients with hypoalbuminemia.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
heart failure